Helsinn Group, a company focused on building quality cancer care, today announces that Phase III data from the largest trial program of its kind to date in anamorelin, a novel, once-daily ghrelin receptor agonist in development for cancer-anorexia-cachexia (CACS) in non-small cell lung cancer will be presented at the 38th European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, in 2014.
Cancer anorexia-cachexia syndrome (CACS), characterized by decreased body weight, mainly lean body mass (LBM), is a common, poorly-understood and debilitating condition in patients with cancer, that frequently occurs in patients with advanced NSCLC, for which existing treatment approaches are limited.
The data will be presented at a session, "Supportive and Palliative Care," by the principal investigator in the study, at a session from 14.00 to 15.45 CET on Saturday September 27th in the Pamplona room, IFEMA, Madrid.
Helsinn will host a press conference at 18.00 CET, September 27th, at the IFEMA to discuss the data and broader issues around the treatment of cancer-anorexia-cachexia in non-small cell lung cancer.
Helsinn's Chief Executive Officer, Mr. Riccardo Braglia, commented: "Helsinn is pleased that data from these pivotal trials are to be presented at ESMO for the treatment of Cancer Anorexia-Cachexia for patients with non-small cell lung cancer.
"Helsinn believes anamorelin may offer the potential for a new approach to treating the symptoms of this multifactorial clinical condition.Cancer Anorexia-Cachexia is a debilitating condition which is distressing for patients and caregivers for whom getting the most out of every day is crucial. We are looking forward to participating in a discussion with some of the world's most eminent cancer specialists about how to move forward towards helping people suffering with this condition."
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis